357 research outputs found
ΠΠ«Π―ΠΠΠΠΠΠ Π ΠΠ‘ΠΠ ΠΠ‘Π’Π ΠΠΠΠΠΠΠ‘Π’Π Π₯Π ΠΠΠΠ§ΠΠ‘ΠΠΠ ΠΠΠ‘Π’Π Π£ΠΠ’ΠΠΠΠΠ ΠΠΠΠΠΠΠ ΠΠΠΠΠΠ₯ Π‘Π ΠΠΠ ΠΠΠ¦ ΠΠΠΠΠΠΠΠ ΠΠΠΠ ΠΠ‘Π’Π
The aim of study was to investigate incidence of chronic obstructive pulmonary disease (COPD) among young people. We examined 1,389 persons (683 men and 706 women, mean age was 30.97 Β± 7.3 years and 29.11 Β± 9.1 years, respectively) using a questionnaire (demographic data, smoking history, respiratory symptoms) and spirography. COPD was diagnosed in 0.5 % of the responders, of them, GOLD I was detected in 57.1 %, GOLD II in 42.9 %; 74.1 % of the participants were smokers.ΠΠ·ΡΡΠ°Π»Π°ΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) ΡΡΠ΅Π΄ΠΈ Π»ΠΈΡ ΠΌΠΎΠ»ΠΎΠ΄ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° (n = 1 389; 683 ΠΌΡΠΆΡΠΈΠ½Ρ ΠΈ 706 ΠΆΠ΅Π½ΡΠΈΠ½; ΡΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ β 30,97 Β± 7,30 ΠΈ 29,11 Β± 9,1 Π³ΠΎΠ΄Π° ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ Π°Π½ΠΊΠ΅ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΠΏΠΎΠ½Π΄Π΅Π½ΡΠΎΠ² (Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅, Π°Π½Π°ΠΌΠ½Π΅Π· ΠΊΡΡΠ΅Π½ΠΈΡ, Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΆΠ°Π»ΠΎΠ±) ΠΈ ΡΠΏΠΈΡΠΎΠ³ΡΠ°ΡΠΈΡ. Π₯ΠΠΠ Π²ΡΡΠ²Π»Π΅Π½Π° Ρ 0,5 % ΠΎΠ±ΡΠ΅Π³ΠΎ ΡΠΈΡΠ»Π° ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
(I ΡΡΠ΅ΠΏΠ΅Π½Ρ β Ρ 57,1 %, II β Ρ 42,9 % ΡΠ΅ΡΠΏΠΎΠ½Π΄Π΅Π½ΡΠΎΠ²), ΡΡΠ΅Π΄ΠΈ ΠΊΡΡΡΡΠ΅Π³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΠ»Π° Π΄Π°Π½Π½ΠΎΠ΅ ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΎ 1,7 %. Π€Π°ΠΊΡΠΎΡΠΎΠΌ ΡΠΈΡΠΊΠ° Ρ 74,1 % Π±ΠΎΠ»ΡΠ½ΡΡ
Π₯ΠΠΠ ΡΠ²ΠΈΠ»ΠΎΡΡ ΡΠ°Π±Π°ΠΊΠΎΠΊΡΡΠ΅Π½ΠΈΠ΅
Current therapeutic approaches to haemostasis correction in covid-19: a systematic review
Background. The coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus has swept across countries worldwide. Despite an unprecedented volume of research, few drug therapies have been proved effective. The lack of evidence-based strategies entailed many practical treatments. Hypercoagulability observed in COVID-19 patients has sparked a debate in the medical community on therapeutic value of anticoagulants.Objectives. A review of up-to-date evidence supporting the therapeutic effect of unfractionated and low molecular-weight heparin as anticoagulant in treatment for COVID-19. Methods. Russian-language and foreign literature was mined in the RSCI, Scopus, PubMed, medRxiv and eLibrary databases for the years 2020β2021, with considering selected impactive publications within 1991β2019 as well. The query keywords were COVID-19, heparin [Π³Π΅ΠΏΠ°ΡΠΈΠ½], hemostasis [Π³Π΅ΠΌΠΎΡΡΠ°Π·], thromboembolism [ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΡ]. Peer-reviewed scientific journals received priority. Content and descriptive analytics were used as research tools.Results. The review surveyed 84 literature sources, with 51 articles selected for downstream analysis. We highlight usage of heparin and its fractions in treatment for COVID-19 and preclinical evidence verifying the antiviral and anti-inflammatory properties of heparin and synthetic heparin-like drugs in COVID-19. The known and plausible side effects demanding additional prospective randomised controlled trials on anticoagulant application in COVID-19 are reviewed, with an assessment of oral direct-acting anticoagulant drug efficiency.Conclusion. Drug-based therapies for haemostasis correction in COVID-19 are currently limited. The paucity of evidence warrants heparin usage as a safer therapy in acute COVID-19 compared to oral anticoagulants. However, the balance of its potential benefits vs. risks must be observed. The benefits and risk uncertainty in heparin treatment require randomised clinical trials and further studies to evaluate safety of direct-acting oral anticoagulants after the patientβs discharge in COVID-19
Dynamics of indices of immune system during different causes of the bronchial asthma exacerbation
The important task in treatment of patients with the bronchial asthma is achievement and long maintenance of illness monitoring. There are no exact data about changes of systemic immunity during various phases of illness at different trigger moments. In our research the most frequent causes leading to hard bronchial asthma exacerbation, dynamics of changes of systematic immunity during various illness phases depending on different causes of exacerbation werw analysed.ΠΠ°ΠΆΠ½ΠΎΠΉ Π·Π°Π΄Π°ΡΠ΅ΠΉ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ
Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π½Π°Π΄ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ. ΠΡΡΡΡΡΡΠ²ΡΡΡ ΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎΠ± ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡΡ
ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° Π² ΡΠ°Π·Π½ΡΠ΅ ΡΠ°Π·Ρ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠΈΠ³Π³Π΅ΡΠ½ΡΡ
ΠΌΠΎΠΌΠ΅Π½ΡΠ°Ρ
. Π Π½Π°ΡΠ΅ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΡΠ΅ ΠΏΡΠΈΡΠΈΠ½Ρ, ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΠΈΠ΅ ΠΊ ΡΡΠΆΠ΅Π»ΡΠΌ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡΠΌ Π°ΡΡΠΌΡ, ΡΠΏΠ΅ΠΊΡΡ ΠΌΠΈΠΊΡΠΎΡΠ»ΠΎΡΡ, ΠΈΠΌΠ΅ΡΡΠ΅ΠΉ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΡΡ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ Π² ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΈ Π°ΡΡΠΌΡ, Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΡΠ°Π·Ρ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΏΡΠΈΡΠΈΠ½ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡ
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½ΠΎΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΡΠΎΠ½Ρ ΠΎΠ»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ Π² ΠΠΎΡΠΎΠ΄ΡΠΊΠΎΠΌ ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ΅Π½ΡΡΠ΅ Π§Π΅Π»ΡΠ±ΠΈΠ½ΡΠΊΠ°
Summary. Since November, 2012, patients with chronic lung disease, chronic heart failure (CHF) or a history of myocardial infarction have being actively vaccinated using 13-valent conjugated pneumococcal vaccine, in Chelyabinsk pulmonological centre. To December, 2013, 103 patients have been vaccinated. Safety of 13-valent conjugated pneumococcal vaccine was evaluated in all vaccinated patients. Efficacy was evaluated in 61 patients (21 with chronic obstructive pulmonary disease (COPD), 10 with bronchiectasis, 26 with COPD and asthma, and 4 with CHF. The vaccine efficacy was evaluated in a year after the vaccination. We found 4.8-fold reduction in exacerbation number in COPD patients, 4.1-fold reduction in bronchiectasis patients and 2.3-fold reduction in patients with COPD and asthma. Number of hospitalisations decreased in 9, 8 ΠΈ 2.2 times, respectively; number of pneumonias decreased in 6; 4.1 and 2.3 times, respectively.Π Π΅Π·ΡΠΌΠ΅. Π ΠΠΎΡΠΎΠ΄ΡΠΊΠΎΠΌ ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ΅Π½ΡΡΠ΅ (Π§Π΅Π»ΡΠ±ΠΈΠ½ΡΠΊ) Ρ Π½ΠΎΡΠ±ΡΡ 2012 Π³. ΠΏΠΎ Π΄Π΅ΠΊΠ°Π±ΡΡ 2013 Π³. Π² ΡΠ°ΠΌΠΊΠ°Ρ
Π°ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ 13-Π²Π°Π»Π΅Π½ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΡΠ³ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½ΠΎΠΉ (ΠΠΠ13) Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ (n = 104) Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ Π»Π΅Π³ΠΊΠΈΡ
, ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ ΠΈ ΠΏΠΎΡΡΠΈΠ½ΡΠ°ΡΠΊΡΠ½ΡΠΌ ΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΊΠ»Π΅ΡΠΎΠ·ΠΎΠΌ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΠΠ13 ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
(n = 61). Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
β Π₯ΠΠΠ (n = 21), Π±ΡΠΎΠ½Ρ
ΠΎΡΠΊΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ (n = 10), ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯ΠΠΠ ΠΈ Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ (n = 26), Π° ΡΠ°ΠΊΠΆΠ΅ Ρ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡΡ (n = 4). ΠΠΎΠ»ΡΡΠ΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅, ΡΠΊΠ°Π·ΡΠ²Π°ΡΡΠΈΠ΅ Π½Π° Π²ΡΡΠΎΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΠΠ13 Π²ΠΎ Π²ΡΠ΅Ρ
Π³ΡΡΠΏΠΏΠ°Ρ
ΡΠ΅ΡΠ΅Π· 1 Π³ΠΎΠ΄ ΠΏΠΎΡΠ»Π΅ Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΠΈ. Π£ΠΌΠ΅Π½ΡΡΠΈΠ»ΠΎΡΡ ΡΠΈΡΠ»ΠΎ: ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ β Π² 1-ΠΉ Π³ΡΡΠΏΠΏΠ΅ β Π² 4,8 ΡΠ°Π·Π°; Π²ΠΎ 2-ΠΉ β Π² 4,1 ΡΠ°Π·Π°; Π² 3-ΠΉ β Π² 2,3 ΡΠ°Π·Π°; ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΉ β Π² 6,0; 4,1 ΠΈ 2,3 ΡΠ°Π·Π°; Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ β Π² 9,0; 8,0 ΠΈ 2,2 ΡΠ°Π·Π° ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ
ΠΠΎΠ²ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π½Π°Π΄ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ
The study was aimed at evaluating efficacy of inhaled combination of hypertonic saline solution and hyaluronic acid in patients with chronic obstructive pulmonary disease (COPD). Methods. Male patients with COPD (n = 99) were involved in the study. Of them, 50 patients were treated with the standard therapy including bronchodilators and mucolytics and 49 patients were treated with bronchodilators and the inhaled combination of 7% hypertonic saline solution and 0.1% solution of hyaluronic acid via a nebulizer, 5 ml b.i.d. during 5 days. Both groups were additionally divided into B, C, and D categories according to severity of symptoms and a rate of exacerbations. The patients were followed-up for 6 months. Clinical and functional parameters including number of exacerbations of COPD and number of hospitalizations were analyzed. Results. Treatment with the inhaled combination of hypertonic saline solution and hyaluronic acid allowed decrease in number of exacerbations of COPD and number of hospitalizations due to exacerbations. Conclusion. The inhaled combination of hypertonic saline solution and hyaluronic acid allowed better control of COPD and could substitute therapeutic bronchoscopy. The combination is well tolerated, has acceptable safety profile without serious adverse events and is convenient to use.Π ΡΡΠ°ΡΡΠ΅ ΠΎΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ), Π½ΠΎΠ²ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π½Π°Π΄ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ. ΠΡΠΈΠ²ΠΎΠ΄ΠΈΡΡΡ ΠΎΠΏΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° 7%-Π³ΠΎ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°ΡΡΠ²ΠΎΡΠ° (ΠΠ ) NaCl ΠΈ 0,1%-Π½ΠΎΠΉ Π³ΠΈΠ°Π»ΡΡΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ (ΠΠ) Π² ΠΠΎΡΠΎΠ΄ΡΠΊΠΎΠΌ ΠΊΠΎΠ½ΡΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ΅Π½ΡΡΠ΅ (Π§Π΅Π»ΡΠ±ΠΈΠ½ΡΠΊ). ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯ΠΠΠ (n = 99) ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΠ»Π°, ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π½Π° 2 Π³ΡΡΠΏΠΏΡ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π½Π°Π·Π½Π°ΡΠ΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ: 1-Ρ (n = 50) β ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΠ΅ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π₯ΠΠΠ (Π±ΡΠΎΠ½Ρ
ΠΎΠ΄ΠΈΠ»Π°ΡΠ°ΡΠΎΡΡ, ΠΌΡΠΊΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ); 2-Ρ (n = 49) β ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ 7%-Π³ΠΎ ΠΠ NaCl + 0,1 %-Π½Π°Ρ ΠΠ Π² Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΠΊ Π±ΡΠΎΠ½Ρ
ΠΎΠ΄ΠΈΠ»Π°ΡΠΈΡΡΡΡΠ΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΡΠ΅ΠΏΠ°ΡΠ°Ρ Π½Π°Π·Π½Π°ΡΠ°Π»ΡΡ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΠΎ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΠΎ ΡΠ΅ΡΠ΅Π· Π½Π΅Π±ΡΠ»Π°ΠΉΠ·Π΅Ρ, ΠΏΠΎ 5 ΠΌΠ» 2 ΡΠ°Π·Π° Π² Π΄Π΅Π½Ρ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 5β7 Π΄Π½Π΅ΠΉ. Π ΡΠ²ΠΎΡ ΠΎΡΠ΅ΡΠ΅Π΄Ρ, ΠΊΠ°ΠΆΠ΄Π°Ρ Π³ΡΡΠΏΠΏΠ° ΠΏΠΎΠ΄ΡΠ°Π·Π΄Π΅Π»ΡΠ»Π°ΡΡ Π½Π° 3 ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΡ ΠΏΠΎ Π³ΡΠ°Π΄Π°ΡΠΈΠΈ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΠΈ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ (B, C, D). ΠΠ΅ΡΠΈΠΎΠ΄ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ» 6 ΠΌΠ΅Ρ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ, ΡΠΈΡΠ»ΠΎ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ Π₯ΠΠΠ ΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠ΅ΠΏΠ°ΡΠ°Ρ 7%-Π³ΠΎ ΠΠ NaCl Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ 0,1 %-Π½ΠΎΠΉ ΠΠ 5 ΠΌΠ» ΡΠ΅ΡΠ΅Π· Π½Π΅Π±ΡΠ»Π°ΠΉΠ·Π΅Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΠΎΠ²Π°ΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π₯ΠΠΠ. ΠΡΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π² ΠΏΠ»Π°Π½ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ½ΠΈΠΆΠ°Π΅ΡΡΡ ΡΠΈΡΠ»ΠΎ ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ Π₯ΠΠΠ ΠΈ ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ Π½ΠΈΠΌΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° 7%-Π³ΠΎ ΠΠ NaCl Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ 0,1 %-Π½ΠΎΠΉ ΠΠ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΡΡΡ ΠΊΠ°ΠΊ Π²Π°ΡΠΈΠ°Π½Ρ Π½Π΅ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠΉ ΡΠ°Π½Π°ΡΠΈΠΎΠ½Π½ΠΎΠΉ Π±ΡΠΎΠ½Ρ
ΠΎΡΠΊΠΎΠΏΠΈΠΈ. ΠΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΈΠΌΠ΅Π΅Ρ Ρ
ΠΎΡΠΎΡΠΈΠΉ ΠΏΡΠΎΡΠΈΠ»Ρ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ, Π½Π΅ ΠΈΠΌΠ΅Π΅Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΡ
ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΡΡΠ΅ΠΊΡΠΎΠ², Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΡΠ΄ΠΎΠ±Π΅Π½ Π² ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ.
Silicosis and cardiovascular pathology
The purpose of the present work was studying densities of a cardiovascular pathology at workers of the large machine-building enterprise, exposed to influence of a silicate dust. 55 patients (man) who had the long contact in the anamnesis with a silicon dust on the manufacture, participated in research. Daily electrocardiogram Holter monitoring, spirometry, an echocardiography, have been examined.Π¦Π΅Π»ΡΡ Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΡΠ°Π±ΠΎΡΡ Π±ΡΠ»ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΄Π΅Π»ΡΠ½ΠΎΠ³ΠΎ Π²Π΅ΡΠ° ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Ρ ΡΠ°Π±ΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΊΡΡΠΏΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΈΠ½ΠΎΡΡΡΠΎΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄-ΠΏΡΠΈΡΡΠΈΡ, ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π°ΡΡΠΈΡ
ΡΡ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΠΈΠ»ΠΈΠΊΠ°ΡΠ½ΠΎΠΉ ΠΏΡΠ»ΠΈ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠ°ΡΡΠ²ΠΎΠ²Π°Π»ΠΎ 55 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (ΠΌΡΠΆΡΠΈΠ½Ρ), ΠΊΠΎΡΠΎΡΡΠ΅ ΠΈΠΌΠ΅Π»ΠΈ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΊΠΎΠ½ΡΠ°ΠΊΡ Ρ ΠΊΡΠ΅ΠΌΠ½ΠΈΠ΅Π²ΠΎΠΉ ΠΏΡΠ»ΡΡ Π½Π° ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π΅. ΠΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΏΠΈΡΠΎΠ³ΡΠ°ΡΠΈΠΈ, ΡΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΠΠ, ΡΡ
ΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΠΈ
ΠΠΏΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΠ΅ΡΠΎΠ΄ΡΠ°Π»Π°-Π ΠΏΡΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ Ρ ΡΠ°Π±ΠΎΡΠΈΡ Π½Π° ΠΏΡΠΎΠΌΡΡΠ»Π΅Π½Π½ΠΎΠΌ ΠΏΡΠ΅Π΄ΠΏΡΠΈΡΡΠΈΠΈ
Chronic obstructive pulmonary disease (COPD) is an actual healthcare problem due to its widespread, progressive course and mortality. A great deal of the patientsβ treatment takes a symptomatic therapy. Results of outpatient treatment with Berodual-N of patients with COPD stage 1 to 2 in stable condition are shown in the article. A significant improvement in clinical signs, lung function parameters (FEV1) and physical tolerance were noted.Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½Π°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΎΠΉ Π΄Π»Ρ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ ΠΈΠ·-Π·Π° ΡΠΈΡΠΎΠΊΠΎΠΉ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ, ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ. ΠΠ½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΌΠ΅ΡΡΠΎ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π₯ΠΠΠ Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΉ ΠΠ΅ΡΠΎΠ΄ΡΠ°Π»Π°-Π Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯ΠΠΠ IβII ΡΡΠ°Π΄ΠΈΠΈ ΠΏΡΠΈ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠΈ Π½Π° Π°ΠΌΠ±ΡΠ»Π°ΡΠΎΡΠ½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅. ΠΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ², ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ Π²Π½Π΅ΡΠ½Π΅Π³ΠΎ Π΄ΡΡ
Π°Π½ΠΈΡ (ΠΠ€Π1) ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΠΎΡΡΠΈ ΠΊ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°Π³ΡΡΠ·ΠΊΠ΅
- β¦